GALECTO, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 22nd, 2020 • Galecto Inc. • Pharmaceutical preparations • New York
GALECTO, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●] Subordinated Debt SecuritiesIndenture • November 4th, 2021 • Galecto, Inc. • Pharmaceutical preparations • New York
INDENTURE, dated as of [●], among GALECTO, INC., a corporation existing under the laws of the State of Delaware (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • November 4th, 2021 • Galecto, Inc. • Pharmaceutical preparations • New York
Galecto, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.00001 per share (the “Common Shares”), having an aggregate offering price of up to $50,000,000 on the terms set forth in this agreement (this “Agreement”).
GALECTO, INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENTDirector Indemnification Agreement • October 22nd, 2020 • Galecto Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [Date] by and between Galecto, Inc, a Delaware corporation (the “Company”), and [Director Name] (“Indemnitee”).
GALECTO, INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENTOfficer Indemnification Agreement • October 22nd, 2020 • Galecto Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [Date] by and between Galecto, Inc., a Delaware corporation (the “Company”), and [Officer Name] (“Indemnitee”). 1
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 22nd, 2020 • Galecto Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 25th day of September, 2020, by and among Galecto, Inc., a Delaware corporation (the “Company”), and each of the stockholders listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
Employment Contract Galecto Biotech ApS and Bertil E. LindmarkEmployment Contract • October 7th, 2020 • Galecto Inc. • Pharmaceutical preparations
October 19, 2023 Garrett Winslow [Address] Re: Retention Compensation Dear Garrett:Retention Compensation Agreement • August 12th, 2024 • Galecto, Inc. • Pharmaceutical preparations • Massachusetts
As you know, Galecto, Inc. (or its affiliate as applicable, the “Company”) greatly appreciates your efforts and hopes to continue working with you in the future. In order to encourage your continued efforts for the Company, the Company is offering you the opportunity to receive retention compensation as specified below, subject to this “Agreement”:
SERVICE AGREEMENT March 2013Service Agreement • October 7th, 2020 • Galecto Inc. • Pharmaceutical preparations
Addendum to the Employment Contract Galecto Biotech ApS CVR no. 34 87 83 66 Ole Maal0es Vej 3 DK-2200 Copenhagen (the “Company’’) and Anders H. Pedersen (the “Employee’’) (each a “Party” and jointly the “Parties”) have today entered into this addendum...Employment Contract • October 7th, 2020 • Galecto Inc. • Pharmaceutical preparations
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • October 7th, 2020 • Galecto Inc. • Pharmaceutical preparations
This amendment to the Employment Agreement of Jonathan Freve is made and entered into between Galecto, Inc. (the “Company”), and Jonathan Freve, (the “Employee” or “You”), (together, the “Parties”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMITTED INFORMATION HAS BEEN REPLACED BY ASTERISKSBonus Agreement • November 6th, 2023 • Galecto, Inc. • Pharmaceutical preparations
have today entered into this retention bonus agreement (the "Bonus Agreement") relating to the service agreement between the Parties, dated 23 April 2013 (the “Service Agreement”).
English Summary of a lease agreement dated May 4, 2020 (the “Lease”) by and between Galecto Biotech ApS (“Galecto”) and COBIS A/S (the “Landlord”)Lease Agreement • October 22nd, 2020 • Galecto Inc. • Pharmaceutical preparations
• Modifications to leased Premises: Galecto is permitted to effect modifications to the leased premises only with the prior written approval of the Landlord. Galecto and the Landlord will agree on the costs, reimbursement and potential obligations to build-back modifications.
September 26, 2023 Jonathan Freve [Address Omitted] Re: Retention Compensation Dear Jon:Retention Compensation Agreement • November 6th, 2023 • Galecto, Inc. • Pharmaceutical preparations • Massachusetts
As you know, Galecto, Inc. (or its affiliate as applicable, the “Company”) greatly appreciates your efforts and hopes to continue working with you in the future. In order to encourage your continued efforts for the Company, the Company is offering you the opportunity to receive retention compensation as specified below, subject to this “Agreement”:
GALECTO, INC. SUPPORT AGREEMENTSupport Agreement • October 7th, 2024 • Galecto, Inc. • Pharmaceutical preparations • Delaware
THIS SUPPORT AGREEMENT (this “Agreement”), dated as of October 7, 2024 is made by and among Galecto, Inc., a Delaware corporation (“Buyer”), Bridge Medicines LLC, a Delaware limited liability company (the “Seller”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of the Buyer.
EMPLOYMENT CONTRACT December 2012Employment Agreement • October 7th, 2020 • Galecto Inc. • Pharmaceutical preparations
ContractLease Agreement • August 5th, 2021 • Galecto, Inc. • Pharmaceutical preparations
English Summary of a lease agreement dated April 15, 2021 (the “Lease”) by and between Galecto Biotech ApS (“Galecto”) and Symbion A/S (the “Landlord”)
